Company Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.
The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease.
It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions.
Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019.
The company was incorporated in 2011 and is headquartered in Bothell, Washington.
| Country | United States |
| IPO Date | Sep 18, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Dr. Mark J. Litton M.B.A., Ph.D. |
Contact Details
Address: 18706 North Creek Parkway Bothell, Washington United States | |
| Website | https://www.athira.com |
Stock Details
| Ticker Symbol | ATHA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001620463 |
| CUSIP Number | 04746L104 |
| ISIN Number | US04746L1044 |
| Employer ID | 45-3368487 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark J. Litton M.B.A., Ph.D. | President, Chief Executive Officer & Director |
| Dr. Javier San Martin M.D. | Chief Medical Officer |
| Dr. Kevin Church Ph.D. | Chief Scientific Officer |
| Julie Rathbun | Head of Investor Relations |
| Mark F. Worthington J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary |
| Robert Renninger | Vice President of Finance, Principal Financial Officer & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Nov 07, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 31, 2024 | SC 13D/A | [Amend] Filing |